Co-expressed microRNAs associated with elevated psychometabolic risk phenotype in women during midlife
-
By
-
Kayla D. Longoria
-
Benjamin M. Stroebel
-
Meghana Gadgil
-
Nicole Perez
-
Kimberly A. Lewis
-
Sandra Weiss
-
Elena Flowers
-
June 23, 2026
-
Clinical Scorecard: MicroRNAs Linked to Increased Psychometabolic Risk Profiles in Midlife Women
At a Glance
| Category | Detail |
|---|
| Condition | Co-occurring Depression and Type 2 Diabetes |
| Key Mechanisms | MicroRNAs associated with risk profiles |
| Target Population | Women aged 40-64 years |
| Care Setting | Diabetes Prevention Program |
Key Highlights
- Two distinct multimorbid risk profiles identified in midlife women.
- High-risk profile associated with younger age, higher adiposity, and depression symptoms.
- MicroRNAs miR-320a and miR-320c linked to increased odds of high-risk profile.
- Black race showed at least threefold higher odds of high-risk profile assignment.
- Study emphasizes the need for multidimensional approaches in risk stratification.
Guideline-Based Recommendations
Diagnosis
- Utilize Beck Depression Inventory (BDI-I) for assessing depression symptoms.
Management
- Consider integrated approaches for managing co-occurring T2D and depression.
Monitoring & Follow-up
- Regularly monitor glycemic biomarkers and mental health indicators in midlife women.
Risks
- Increased risk of T2D and depression co-occurrence in midlife women.
Patient & Prescribing Data
Midlife women with risk factors for T2D and depression.
MicroRNAs may serve as biomarkers for identifying high-risk individuals.
Clinical Best Practices
- Implement routine screening for both T2D and depression in midlife women.
- Focus on lifestyle interventions targeting both mental and physical health.
Related Resources & Content
